DGKG — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21830991	1.00	2/20
SCHEMBL23293507	0.87	2/20
SCHEMBL23293148	0.84	2/20
SCHEMBL23293265	0.84	2/20
SCHEMBL23293307	0.84	2/20
SCHEMBL23293196	0.83	2/20
SCHEMBL23293138	0.83	2/20
SCHEMBL23293147	0.81	2/20
SCHEMBL23293186	0.81	2/20
SCHEMBL23293506	0.81	2/20
SCHEMBL23293193	0.79	2/20
SCHEMBL23293351	0.79	2/20
SCHEMBL23293353	0.79	2/20
SCHEMBL23293169	0.78	2/20
SCHEMBL23293415	0.78	2/20
SCHEMBL23293349	0.76	2/20
SCHEMBL23293461	0.76	2/20
SCHEMBL23293182	0.76	2/20
SCHEMBL23293369	0.76	2/20
SCHEMBL23293563	0.76	2/20

Clinical trials — most relevant to DGKG by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate	PHASE2/PHASE3	WITHDRAWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)	PHASE2	COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans	nan	COMPLETED
Tissue Lipids and Insulin Resistance	nan	WITHDRAWN
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism	nan	COMPLETED
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity.	nan	UNKNOWN
The Role of Arachidonic Acid Metabolites, From Patients With Metabolic Syndrome	nan	UNKNOWN
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH	nan	COMPLETED
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome	nan	UNKNOWN
Study of Changes in Skeletal Muscle After Caloric Restriction	nan	ACTIVE_NOT_RECRUITING
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Effect of Age on Glucose and Lipid Metabolism	nan	COMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome	nan	COMPLETED
Effects of Obesity and Intensity of Exercise on Ghrelin Levels	nan	COMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
The Effect of Lowered Physical Activity on Insulin Sensitivity and Lipid and Glucose Metabolism	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DGKG binder may also engage these)

Protein	Name	Similarity
DGKA	Diacylglycerol kinase alpha	1.000	landscape →
P20192	—	1.000	P20192 →
Q91WG7	—	1.000	Q91WG7 →
P51556	—	1.000	P51556 →
DGKB	Diacylglycerol kinase beta	1.000	landscape →
Q39017	—	1.000	Q39017 →
O88673	—	1.000	O88673 →
P49620	—	1.000	P49620 →
Q6NS52	—	1.000	Q6NS52 →
A0JN54	—	1.000	A0JN54 →
P49621	—	1.000	P49621 →
Q03603	—	1.000	Q03603 →
Q9FFN7	—	1.000	Q9FFN7 →
KAT8	Histone acetyltransferase KAT8	0.998	landscape →
Q6P5E8	—	0.998	Q6P5E8 →
B4NBB0	—	0.996	B4NBB0 →
Q6C710	—	0.995	Q6C710 →
P25799	—	0.995	P25799 →
Q5XI06	—	0.995	Q5XI06 →
KDM5D	Lysine-specific demethylase 5D	0.995	landscape →
Q61T02	—	0.995	Q61T02 →
Q9TYU5	—	0.994	Q9TYU5 →
Q6IQX0	—	0.994	Q6IQX0 →
Q9H1H9	—	0.994	Q9H1H9 →
P10686	—	0.994	P10686 →
B4LX81	—	0.994	B4LX81 →
PLCG1	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1	0.994	landscape →
Q22070	—	0.994	Q22070 →
Q62077	—	0.994	Q62077 →
P22717	—	0.994	P22717 →